HR Execs on the Move

Eichen Crutchlow Zaslow LLP

www.njadvocates.com

 
Eichen Crutchlow Zaslow LLP, with offices located in Edison, New Jersey, is recognized as one of the pre-eminent medical malpractice and personal injury law firms in New Jersey. The firm is highly regarded among legal professionals for their effective and aggressive representation based on intelligent and innovative strategies for recovering maximum compensation on behalf of victims of negligence. Clients recognize the attorneys and staff for providing the highest level of responsive client service and compassionate understanding of how devastating a catastrophic personal injury or death can be to an individual and family. The attorneys have extensive experience in all areas of ...
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Kona Capital

Kona Capital is a Boise, ID-based company in the Business Services sector.

Bolt Self Storage

We are dedicated to offering top notch customer service! We are committed to offering you exceptional value for your hard earned money.

2nd Story Media

2nd Story Media is a San Jose, CA-based company in the Business Services sector.

Alphabet Creative

Alphabet Creative is a Ottawa, ON-based company in the Business Services sector.

Mural Oncology

We know that drug development is both an art and a science. The work we do is incredibly technical, intentional, and specific, but there is an art to it - because we must leave room for creativity, innovation and spontaneity. Murals are paintings that transform overlooked or unused spaces - creating something impactful and meaningful. There remains many overlooked opportunities in cancer drug development. This is what inspires us. Our mission is simple, to create novel immunotherapies that can change patients lives so they can get back to what matters most - living. Mural Oncology is leveraging its industry-leading protein engineering platform to revolutionize cytokine-based immunotherapies for the treatment of cancer. Immunotherapies have been transformative for some people living with cancer, but unfortunately many patients still do not benefit - either because they are ineligible for treatment or they do not respond well to current therapies. We leverage our expertise in cytokine biology, immune cell modulation and our protein engineering capabilities to develop first and novel immunotherapies. Our goal is to deliver meaningful, clinical benefit across a wide range of cancers, including tumor types where immunotherapies have previously not been effective. Mural Oncology is developing a portfolio of programs to broaden the potential and reach of cytokine-based immunotherapies for the treatment of cancers. (NASDAQ: MURA)